Quantcast

Latest hepatitis C Stories

2014-05-07 08:32:30

-- Filing Includes Data from Treatment-Naive Patients with Advanced Fibrosis and Null Responders with All Stages of Liver Fibrosis -- RARITAN, N.J., May 7, 2014 /PRNewswire/ -- Janssen Research & Development, LLC (Janssen) today announced it has submitted a Supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for simeprevir, an NS3/4A protease inhibitor marketed as OLYSIO(TM) in the United States, in combination with the nucleotide analog NS5B polymerase...

2014-05-07 08:31:43

DELAND, Fla., May 7, 2014 /PRNewswire/ -- DaVita Kidney Care, a division of DaVita HealthCare Partners Inc. (NYSE: DVA) and a leading provider of kidney care services, today announced that DaVita Labs, the diagnostic laboratory servicing both dialysis organizations and physician practices, has implemented molecular diagnostic testing using technology from Roche Diagnostics. http://photos.prnewswire.com/prnvar/20140318/DC85712LOGO This molecular diagnostic testing will allow DaVita...

2014-05-02 12:26:36

New research finds Vietnam vets with hepatitis C do not have higher rates of the disease DANVILLE, Pa., May 2, 2014 /PRNewswire-USNewswire/ -- A team of researchers from four health systems across the United States has published a study revealing that Vietnam era vets with hepatitis C virus (HCV) do not have higher rates of this disease due to injection drug abuse compared to nonveterans. The study was published electronically in the Journal of Community Health in April. It is...

2014-05-01 23:09:09

Three of BioPlus’ Doctors of Pharmacy will be presenting at the 10th Annual Specialty Pharmacy Summit, providing insight about specialty pharmacy cost savings. Altamonte Springs, FL (PRWEB) May 01, 2014 BioPlus Specialty Pharmacy (BioPlus), one of the nation’s largest specialty pharmacies specializing in hepatitis C, will be involved in educational panels at Armada’s 2014 Annual Specialty Pharmacy Summit & Expo. The BioPlus speakers will focus on the changing landscape of...

2014-05-01 23:06:55

MedSpring Offering Free Hepatitis C Screenings in May Austin, TX (PRWEB) May 01, 2014 According to the CDC, approximately three million Americans are living with hepatitis C and as many as 75 percent do not know they are infected. Hepatitis C virus infection is the most common chronic blood-borne infection in the United States and can lead to serious health issues, including liver disease, cirrhosis, cancer and even death. In recognition of Hepatitis Awareness Month, MedSpring is offering...

2014-04-22 08:34:00

-Submission based on the largest Phase III program in genotype 1 (GT1) hepatitis C patients conducted to date(1) NORTH CHICAGO, Ill., April 22, 2014 /PRNewswire/ -- AbbVie (NYSE: ABBV) submitted its New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for the company's investigational, all-oral, interferon-free regimen for the treatment of adult patients with chronic genotype 1 (GT1) hepatitis C virus (HCV) infection. The NDA is supported by...

2014-04-14 12:51:21

The new interferon-free, all-oral, three direct-acting-antiviral (3D) treatment regimen in development by AbbVie has achieved very high rates of virological response in patients chronically infected with hepatitis C virus (HCV) genotype 1 (GT1); according to the results of three studies presented today at the International Liver CongressTM 2014. The 3D regimen consists of the HCV NS3/4A protease inhibitor ABT-450 dosed with ritonavir, the NS5A inhibitor ABT-267, and the NS5B RNA polymerase...

2014-04-14 12:35:09

Results from RESTORE , a phase III, multicentre, single-arm, open-label study presented today at the International Liver CongressTM 2014 showed that simeprevir 150 mg once-daily for 12 weeks in combination with peginterferon and ribavirin (followed by 12 or 36 weeks of peginterferon and ribavirin) was effective and well tolerated in hepatitis C virus (HCV) genotype 4-infected patients, consistent with previous observations in HCV genotype 1-infected patients. Overall, 65.4% of patients...

2014-04-14 12:05:11

High cure rates achieved with fixed-dose interferon-free and ribavirin-free regimen Results from three Phase III clinical trials (ION-1, ION-2 and ION-3) evaluating the investigational once-daily fixed-dose combination of the nucleotide analogue polymerase inhibitor sofosbuvir (SOF) 400mg and the NS5A inhibitor ledipasvir (LDV) 90mg, with and without ribavirin (RBV), for the treatment of genotype 1 chronic hepatitis C virus (HCV) infection have been presented at the International Liver...

Hepatitis C Treatment Without The Side Effects Of Interferon
2014-04-14 10:21:29

redOrbit Staff & Wire Reports - Your Universe Online A new orally-administered antiviral therapy has reportedly cured hepatitis C infection in over 90 percent of patients with liver cirrhosis, according to research published Saturday in the New England Journal of Medicine. Previously, the only treatment method that showed effectiveness against hepatitis C was interferon. However, patients treated with this agent often suffered relapses and experienced multiple adverse side effects....


Latest hepatitis C Reference Libraries

11_9e88d15808b8ecc3fcbbdfcf4ae75786
2011-01-20 19:23:30

Hepatitis C virus (HCV) is an enveloped, positive-sense single-stranded RNA virus of the family Flaviviridae. It consists of a core of genetic material surrounded by an icosahedra protective shell of protein. The genome consists of a single open reading frame that is 9600 nucleotide bases long. HCV replication takes several steps. It primarily replicates in the hepatocytes of the liver. It can also reproduce in peripheral blood mononuclear cells. There is a wide variety of genotypes and...

More Articles (1 articles) »
Word of the Day
snash
  • To talk saucily.
  • Insolent, opprobrious language; impertinent abuse.
This word is Scots in origin and probably imitative.